Have you been told that you have intrauterine adhesions or fibroids?

Learn about a clinical trial that is evaluating a new product which may prevent them.

In the realm of women’s health, addressing intrauterine adhesions (IUAs) remains a critical concern. These adhesions, often referred to as Asherman’s syndrome, can lead to infertility, menstrual irregularities, and recurrent miscarriages, significantly impacting women’s reproductive health and overall well-being. Hysteroscopy, a minimally invasive procedure, is commonly used for both diagnostic and therapeutic purposes in managing IUAs. However, the risk of adhesion reformation post-hysteroscopy underscores the necessity for innovative preventative measures.

What are intrauterine adhesions?

Commonly referred to as “Asherman’s syndrome”, IUAs are bands of fibrous tissue that form in the uterus, often in response to a uterine procedure. As many as 40% of women who have had some type of surgical procedure inside the uterus develop Asherman’s syndrome. Your doctor can see these adhesions using ultrasound or by putting a thin telescope inside the uterus, a procedure called hysteroscopy.

About Rejoni’s clinical study

The thicker the bands of scar tissue, the more they can cause the uterine cavity to narrow, resulting in pain, skipped, sparse or absent menstrual periods as well as recurring pregnancy loss and other pregnancy complications.

What is this clinical study about?

Working closely with leading physicians, Rejoni™ is conducting a clinical trial to learn if a soft gel-like material called Juveena™ Hydrogel may prevent intrauterine adhesions after uterine surgery.

How does the clinical study work?

In this study, potential participants are those who are undergoing uterine surgery either to remove fibroids or to disrupt existing adhesions in a procedure called adhesiolysis.
Qualified participants will be randomly assigned to either receive instillation of the hydrogel (treatment group) directly after completion of the uterine surgery or to not have the hydrogel instilled (control group). Two women will be assigned to the treatment group for everyone assigned to the control group.

Am I eligible for this clinical study?

If you are at least 18 years old, and your diagnosis through imaging has identified that you should undergo fibroid removal or adhesiolysis, you may be eligible to participate. There is no cost to you to participate in this clinical study.

Learn More About The Study